Special Issue "Diagnosis, Pathogenesis and Treatment of TAFRO Syndrome"
Deadline for manuscript submissions: 31 March 2024 | Viewed by 127
Interests: TAFRO syndrome; iMCD; IgG4-related disease; lymphoid malignancy; sjogren syndorme
This Special Issue, ‘Diagnosis, Pathogenesis and Treatment of TAFRO syndrome’, will mainly focus on the novel severe hyper-inflammatory disorder, called TAFRO syndrome, which was first reported in Japan in 2010. Because lymph node histology is similar in patients with TAFRO syndrome and Castleman disease, TAFRO syndrome is described as a related disorder of Castleman disease; however, the two conditions are markedly different clinically. Cases with hyper-inflammation syndrome, such as TAFRO syndrome, require intensive therapeutic strategy. Further understanding of TAFRO syndrome requires the identification of novel disease-specific biomarkers.
For this Special Issue, we invite authors to submit original research and review articles that focus on the diagnosis, pathogenesis and therapeutic potential of TAFRO syndrome. Potential topics include, but are not limited to, the following:
- Clinical and Pathological diagnosis;
- Relationship and differentiation with iMCD, IPL, POEMS syndrome, malignancies, infections and collagen-vascular disorders;
- Cytokine, chemokine and other factors;
- Therapeutic trials and experiences.
Prof. Dr. Yasufumi Masaki
Prof. Dr. Sadao Aoki
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- hyper-inflammation syndrome
- multicentric Castleman disease
- renal dysfunction
- collagen-vascular disorder